[Form 4] ELI LILLY & Co Insider Trading Activity
Eli Lilly & Co (LLY) director Jamere Jackson reported acquiring common stock of the company. On 11/17/2025, the reporting person acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, coded as an acquisition transaction. Following this transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock held directly. The filing was made as a Form 4 by a single reporting person in the capacity of a company director.
- None.
- None.
FAQ
What did Eli Lilly (LLY) report in this Form 4 filing?
This Form 4 reports that director Jamere Jackson acquired additional common stock of Eli Lilly & Co in a reported transaction on 11/17/2025.
How many Eli Lilly (LLY) shares did the director acquire and at what price?
The director acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share, recorded as an acquisition transaction.
What is the director's total Eli Lilly (LLY) share ownership after this transaction?
After the reported transaction, the director beneficially owns 9,635.494 shares of Eli Lilly common stock, held in direct ownership.
What is the relationship of the reporting person to Eli Lilly (LLY)?
The reporting person, Jamere Jackson, is identified as a Director of Eli Lilly & Co on the Form 4.
Does this Form 4 include any derivative securities for Eli Lilly (LLY)?
No derivative securities are reported as acquired, disposed of, or beneficially owned in Table II of this Form 4; only common stock is listed in Table I.
Was this Eli Lilly (LLY) transaction filed by more than one reporting person?
No. The filing indicates that the Form 4 was filed by one reporting person, not by a group or multiple filers.
What is the purpose of SEC Form 4 for Eli Lilly (LLY) insiders?
Form 4 is used by company insiders, such as directors, to report changes in their beneficial ownership of the issuer's securities, including acquisitions and dispositions.